Peripheral Blood miRome Identified miR-155 as Potential Biomarker of MetS and Cardiometabolic Risk in Obese Patients.

This study explored circulating miRNAs and target genes associated with metabolic syndrome (MetS) and cardiometabolic risk in obese patients. Small-RNA sequencing was used to assess the peripheral blood miRNome of 12 obese subjects (6 MetS and 6 non-MetS). Differentially expressed miRNAs and target genes were further analyzed by qPCR in a larger sample of obese patients (48 MetS and 32 non-MetS). miRNA:mRNA interactions were studied using in silico tools. miRNome analysis identified 10 downregulated miRNAs in MetS compared to non-Met patients ( < 0.05). In silico studies revealed three miRNAs (miR-155, miR-181a, and let-7a) and their predictive targets (CCAAT/enhancer-binding protein beta-, KRAS proto-oncogene, GTPase- and suppressor of cytokine signaling 1-) with a potential role in the insulin receptor signaling pathway. miR-155 expression was reduced and mRNA levels were increased in MetS patients ( < 0.05), and these effects were correlated with the number of MetS diagnostic criteria ( < 0.05). Increased HOMA-IR (>7.6) was associated with low miR-155 levels, high expression, and serum hsCRP ( < 0.05). miR-155 was negatively correlated with , HOMA-IR, and plasma fibrinogen, and positively correlated with serum adiponectin ( < 0.05). Downregulation of circulating miR-155 is associated with insulin resistance, poor glycemic control, and increased MetS-related cardiometabolic risk, and these effects are potentially mediated by interaction with